[关于阿尔茨海默病诊断的生物标志物和检测方法的研究进展在体外]
Y T Zhang1, Z Zhang1, Y C Zhang1
1Department of Laboratory Medicine, Fudan University Affiliated Pudong Medical Center, Shanghai 201399, China.
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
|November 26, 2023
概括
由于阿尔茨海默病的潜伏性,早期诊断阿尔茨海默病 (AD) 是至关重要的. 本综述探讨了最近在体外诊断生物标志物和AD检测方法方面的进展,这对于及时干预和治疗至关重要.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 发现生物标志物的发现.
- 临床诊断 临床诊断 临床诊断
相关概念视频
01:26Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195